Children's Hospital is part of the UPMC family.
This multicenter trial by the Children’s Oncology Group studies the effects of eribulin mesylate for solid tumors and lymphomas that do not respond to other treatment or which have come back after treatment.
Subject to certain exclusion criteria, this study is open to patients of both genders from ages 6 months to 17 years, with refractory or recurrent solid tumors or lymphomas, excluding central nervous system tumors. Patients must have had histologic-verification of malignancy at original diagnosis or relapse and their current disease state must be one for which there is no known curative therapy or therapy proven to prolong survival with an acceptable quality of life.
Males and Females: 6 months to 17 years old
Participants will receive the study drug intravenously on days 1 and 8 of 21-day cycles.
Visits: 2 for each cycle of therapy with evaluations at the end of cycle 1, then evaluations every other cycle for 2 cycles, then every 3 cycles.
Duration: Varies according to treatment response
Children’s Oncology Group (ADVL1314)
National Cancer Institute
Study Description at National Institutes of Health
Gary Mason, MD
For more information about the study or enrollment, please contact:
Research Coordinator Angela Connelly, RN, BSN
Children's Hospital's main campus is located in the Lawrenceville neighborhood. Our main hospital address is:
Children’s Hospital of Pittsburgh of UPMC
One Children’s Hospital Way
4401 Penn Ave.
Pittsburgh, PA 15224
In addition to the main hospital, Children's has many convenient locations in other neighborhoods throughout the greater Pittsburgh region.
With myCHP, you can request appointments, review test results, and more.
For questions about a hospital bill call:
To pay your bill online, please visit UPMC's online bill payment system.
Interested in giving to Children's Hospital? Visit Children's Hospital of Pittsburgh Foundation's website to: